Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates

Int Urol Nephrol. 2024 Sep;56(9):2851-2860. doi: 10.1007/s11255-024-04037-1. Epub 2024 Apr 5.

Abstract

Purpose: Prostate Imaging-Reporting and Data System (PI-RADS) assists in evaluating lesions on multiparametric magnetic resonance imaging (mpMRI), but there are still ongoing efforts in improving the predictive value for the presence of clinically significant PCa (csPCa) with a Gleason grade group ≥ 2 on Fusion-Biopsy. This pilot study intends to propose an easily implementable method for augmenting predictability of csPCa for PI-RADS.

Methods: A cohort of 151 consecutive patients underwent mpMRI Fusion and random US Biopsy as a result of having at least one PI-RADS lesion grade 3-5 between January 1, 2019 and December 31, 2022. A single radiologist reads all films in this study applying PI-RADS V2.

Results: Of the 151 consecutive patients, 49 had a highest lesion of PI-RADS 3, 82 had a highest lesion of PI-RADS 4, and 20 had a highest lesion of PI-RADS 5. For each respective group, 12, 42, and 18 patients had proven csPCa. Two predictive models for csPCa were created by employing a logistical regression with parameters readily available to providers. The models had an AUC of 0.8133 and 0.8206, indicating promising effective models.

Conclusion: PI-RADS classification has relevant predictability problems for grades 3 and 4. By applying the presented risk calculators, patients with PI-RADS 3 and 4 are better stratified, and thus, a significant number of patients can be spared biopsies with potential complications, such as infection and bleeding. The presented predictive models may be a valuable diagnostic tool, adding additional information in the clinical decision-making process for biopsies.

Keywords: MRI-fusion biopsy; Prostate cancer; Risk calculator.

MeSH terms

  • Aged
  • Humans
  • Image-Guided Biopsy* / methods
  • Male
  • Middle Aged
  • Multiparametric Magnetic Resonance Imaging*
  • Pilot Projects
  • Predictive Value of Tests
  • Prostatic Neoplasms* / pathology
  • Retrospective Studies
  • Risk Assessment